Key result
Omega-3 PUFAs administered before PCI reduced CK-MB levels at 8 hours and 24 hours compared to standard therapy, but did not decrease troponin I.
Why the study?
Does pre-procedural administration of omega-3 PUFAs reduce cardiac biomarker elevation in patients undergoing PCI?
RCT (n=90)
randomly assigned
Does pre-procedural administration of omega-3 PUFAs reduce cardiac biomarker elevation in patients undergoing PCI?
Pre-procedural administration of 3g omega-3 PUFAs significantly reduces post-PCI CK-MB elevation, suggesting a protective effect against procedural myocardial injury.
Answers are grounded in this paper and cite their sources.
Omega-3 PUFAs may attenuate post-PCI biomarker rises; leaves open clinical-event benefit in larger trials.
OBJECTIVE: This study sought to investigate the effect of omega-3 polyunsaturated fatty acids (PUFAs) on cardiac biomarkers, CK-MB, and troponin I in patients undergoing PCI. BACKGROUND: Restenosis remains as a major long-term complication following percutaneous coronary intervention (PCI). It appears that there is strong relationship between post-PCI creatine kinase-MB (CK-MB) and troponin I elevation and cardiovascular events after PCI. METHODS: In this randomized clinical trial, a total of 90 patients planned to undergo PCI were randomly assigned into two groups: Group A-receiving omega-3 PUFAs (3 g, 12 h before PCI) plus standard treatment (n = 43) and Group B-control group, receiving only standard therapy (n = 47). Standard treatment included aspirin 325 mg and clopidogrel 600 mg loading dose. The plasma CK-MB level was measured before the procedure (baseline), at 8 and 24 h after PCI. The plasma troponin I was measured at baseline and 24 h after PCI. RESULTS: In comparison with control, omega-3 PUFAs could significantly reduce the level of CK-MB in 8 (P = 0.001) and 24 h (P = 0.012) after its prescription in the omega-3 PUFAs group. Omega-3 PUFAs could not significantly decrease troponin I. CONCLUSION: Our results revealed that omega-3 PUFAs can be considered as a safe adjunctive medication to the standard regimen before PCI for the aim of decreasing cardiovascular event after PCI.
No takes yet. Share an insight, caveat, or question.
Foroughinia et al. (2012) conducted an RCT in patients undergoing PCI (n=90). Omega-3 polyunsaturated fatty acids (PUFAs) vs. Standard therapy (aspirin 325 mg and clopidogrel 600 mg loading dose) was evaluated on Plasma CK-MB and troponin I levels at 8 and 24 hours after PCI (p=0.001). Omega-3 PUFAs administered before PCI reduced CK-MB levels at 8 hours and 24 hours compared to standard therapy, but did not decrease troponin I.
Synapse has enriched 10 related papers. Consider them for comparative context: